pdufa.bio

WVE-210201

Page updated ·next FDA decision on the calendar ·Data as of Oct 13, 2026 11:39 PM ET

WVE-210201 is a Wave Life Sciences, Inc. program. Every date links its source.

WVE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Wave Life Sciences, Inc. (WVE). We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jun 2026WVEReadout · Sep 2026WVE

Specialist biotech funds holding WVE, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management26,975,505$156.7 millionfiled August 14, 2026
RTW Investments1,350,000$7.8 millionfiled August 14, 2026
Baker Bros. Advisors822,638$4.8 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is WVE-210201's next FDA decision or readout?

No upcoming catalyst is on our calendar for WVE-210201; no FDA decisions are on record below.

What happened at WVE-210201's most recent FDA decision?

No FDA decision for WVE-210201 is in our archive yet.

Who makes WVE-210201?

Wave Life Sciences, Inc. (WVE).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.